BRCTF (BioArctic AB) Tariff Resilience Score: 7/10 (As of Jul. 08, 2026)


BRCTF BioArctic AB BRCTF
84 GF Score
Price $35.00
GF Value $49.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioArctic AB Tariff Resilience Score?

BioArctic AB BRCTF 84 Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,367 Biotechnology companies, BioArctic AB ranks better than 90.34% on this metric.

BioArctic AB has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

BioArctic AB has BioArctic AB has limited tariff exposure due to its focus on pharmaceuticals, which often have exemptions. Its supply chain is primarily European, and it has strong partnerships that provide some insulation from tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioArctic AB might have Highly Resilient.

BioArctic AB  (OTCPK:BRCTF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioArctic AB Tariff Resilience Score Related Terms

BRCTF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BioArctic AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Tariff Resilience Score falls into.


BRCTF
84GF Score
BioArctic AB BRCTF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
BioArctic AB (BRCTF) has a Tariff Resilience Score of 7 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioArctic AB ranks #132 out of 1367 companies in the Biotechnology industry, placing it in the top 9.7%.
Is BioArctic AB's Tariff Resilience Score too high?
BioArctic AB's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. BioArctic AB's value of 7 is 75% above this industry median. Based on the distribution chart, BioArctic AB ranks #132 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #132 out of 1367 companies for Tariff Resilience Score. This places BioArctic AB in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. BioArctic AB's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.07, compared to a current price of $35.00 — trading 28.7% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. BioArctic AB's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (BRCTF) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of $35.00 is trading 28.7% below its estimated GF Value™ of $49.07. GuruFocus considers BioArctic AB to be Modestly Undervalued.

Key valuation signals for BRCTF:

  • Tariff Resilience Score: 7
  • GF Value™: $49.07 vs. price of $35.00 (28.7% below fair value)
  • GF Score™: 84/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1367)

No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score

Get the complete analysis for BRCTF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.00
Price
$49.07
GF Value